Merus Stock Price, News & Analysis

Merus (MRUS) reported Q1 2025 financial results and provided business updates. The company's petosemtamab drug shows promising progress with two phase 3 trials expected to be substantially enrolled by year-end 2025. The company plans to present updated interim phase 2 data for petosemtamab in combination with pembrolizumab at the 2025 ASCO Annual Meeting. Financially, Merus reported $638 million in cash and equivalents, expected to fund operations into 2028. Q1 2025 revenue increased by $18.6 million compared to Q1 2024, primarily due to commercial material revenue. However, operating expenses increased significantly, with R&D expenses up by $41.5 million and G&A expenses up by $6.0 million. The company reported a net loss of $96.47 million for Q1 2025, compared to a $34.46 million loss in Q1 2024.

Merus N.V. (Nasdaq: MRUS) announced the acceptance of an abstract for presentation at the 2025 ASCO Annual Meeting in Chicago. The presentation will feature updated interim clinical data from their phase 2 trial of petosemtamab with pembrolizumab as first-line treatment for PD-L1+ recurrent/metastatic head and neck squamous cell carcinoma (HNSCC).

The poster presentation will include data on the complete 45-patient dataset, building upon previously presented early clinical efficacy and safety data from ASCO 2024. According to CEO Bill Lundberg, petosemtamab shows potential as a first and best-in-class treatment for r/m HNSCC, demonstrating substantial clinical activity superior to historical controls across ORR, PFS, and OS metrics.

The presentation is scheduled for June 2, 2025, and Merus will host an investor conference call on May 22, 2025, to discuss the full data set.

Merus N.V. (Nasdaq: MRUS), a biotechnology company specializing in innovative multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), has announced its participation in the 24th Annual Needham Virtual Healthcare Conference.

The company's President and CEO, Bill Lundberg, M.D., will engage in a fireside chat on Tuesday, April 8, 2025, at 8:45 a.m. ET. Investors and interested parties can access the live webcast through the Investors section of the Merus website, where the presentation recording will remain available for a time following the event.

Merus (NASDAQ: MRUS) announced financial results and business updates for Q4 and full year 2024. Key highlights include the FDA approval of BIZENGRI® for NRG1+ pancreatic adenocarcinoma and NSCLC patients, and two Breakthrough Therapy designations for petosemtamab.

The company is advancing two Phase 3 trials for petosemtamab: LiGeR-HN1 (in combination with pembrolizumab for 1L PD-L1+ r/m HNSCC) and LiGeR-HN2 (monotherapy in 2/3L r/m HNSCC), both expected to be substantially enrolled by year-end 2025. Interim data showed a 67% response rate in 1L HNSCC combination therapy and 36% response rate in 2L+ monotherapy.

Financial position remains strong with $724.0 million in cash, cash equivalents and marketable securities as of December 31, 2024, expected to fund operations into 2028.

Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), has announced upcoming investor conference participation.

The company's President and CEO, Bill Lundberg, M.D., will present at two major healthcare investment events:

• TD Cowen 45th Annual Health Care Conference on Tuesday, March 4 at 9:10 a.m. ET
• Leerink Partners Global Healthcare Conference on Monday, March 10 at 11:20 a.m. ET

Webcasts of both presentations will be available live on the Investors page of the Merus website, with archived recordings accessible for a time after each event. The announcement comes as Merus continues to advance its portfolio of novel cancer therapeutics.

Merus N.V. (Nasdaq: MRUS) has received a second Breakthrough Therapy designation (BTD) from the FDA for petosemtamab in combination with pembrolizumab. This designation is for first-line treatment of adult patients with recurrent or metastatic PD-L1 positive head and neck squamous cell carcinoma (r/m HNSCC) with CPS ≥ 1.

The BTD is supported by updated data from an ongoing phase 1/2 trial, which showed a 67% response rate among 24 evaluable patients. This follows the initial BTD and Fast Track designation received in May 2024 and August 2023 for petosemtamab in treating r/m HNSCC patients whose disease progressed after platinum-based chemotherapy and anti-PD-1 antibody treatment.

The BTD status will expedite development and review processes, providing intensive FDA guidance and eligibility for rolling review and priority review. Merus plans to engage with the FDA as they work toward a potential Biologics License Application (BLA) submission.

Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company specializing in innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), has announced its participation in Citi's 2025 Virtual Oncology Leadership Summit. Bill Lundberg, M.D., President and Chief Executive Officer of Merus, will deliver a presentation on Thursday, February 20, 2025, at 9:00 a.m. ET.

The presentation will be accessible via webcast on the Investors section of the company's website both during and after the event for a time.

Merus N.V. (MRUS) announced the publication of results from their registrational phase 2 eNRGy trial for Bizengri® (zenocutuzumab) in the New England Journal of Medicine. The drug is the first treatment specifically indicated for adults with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) harboring NRG1 gene fusion who experienced disease progression after prior therapy.

The study enrolled 204 patients across 12 tumor types, demonstrating durable efficacy particularly in NSCLC and pancreatic adenocarcinoma cases, with a favorable safety profile. In December, Merus licensed exclusive U.S. commercialization rights to Partner Therapeutics.

The drug's safety profile showed notable adverse reactions, including infusion-related reactions in 13% of patients (all Grade 1 or 2), and interstitial lung disease/pneumonitis in 1.1% of patients. The approval is based on overall response rate and duration of response, with continued approval contingent on confirmatory trials.

Merus N.V. (MRUS) and Biohaven (BHVN) have announced a research collaboration and license agreement to co-develop three novel bispecific antibody drug conjugates (ADCs). The partnership combines Merus' Biclonics® technology platform with Biohaven's ADC conjugation and payload platform technologies.

The collaboration includes two Merus bispecific programs and one program under preclinical research. Biohaven will handle preclinical ADC generation under mutually agreed research plans. Both companies will share subsequent external development costs and commercialization upon program advancement.

Merus will receive an upfront payment and license fee at ADC candidate nomination of the first program. Merus will cover preclinical bispecific antibody generation costs, while Biohaven will manage preclinical ADC generation costs.